1.Lang I, Brodowicz T, Ryvo L et al. Bevacizumab plus paclitaxel vs bevacizumab plus capecitabine as first - line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open - label, non - inferiority, phase 3 TURANDOT trial 2013. http://dx.doi.org/10.1016/S1470-2045(12)70566-12.Rossari J.R, Metzger-Filho O, Paesmans M et al. Bevacizumab and breast cancer: a meta - analysis of first - line phase III studies and a critical reappraisal of available evidence. J Oncol 2012; 417 673.3.Brufsky A, Valero V, Tiangco B et al. Second - line bevacizumab - containing therapy in patients with triple - negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012; 133 (3): 1067–75.4.von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366 (4): 299–309.5.Lang I, Brodowicz T, Ryvo L et al. Central European Cooperative Oncology Group. Bevacizumab plus paclitaxel vs bevacizumab plus capecitabine as first - line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open - label, non - inferiority, phase 3 TURANDOT trial. Lancet Oncol 2013; 14 (2): 125–33.6.Cortes J, Calvo V, Ramírez-Merino N et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta - analysis. Ann Oncol 2012; 23 (5): 1130–7.7.Gray R, Bhattacharya S et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel vs paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27 (30): 4966–72. http://doi:10.1200/ JCO.2008.21.66308.Miles D.W, Chan A, Dirix L.Y et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first - line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28 (20): 3239–47.9.Croom K.F, Dhillon S. Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first - line therapy for HER2-negative metastatic breast cancer. Drugs 2011; 71 (16): 2213–29.10.Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab vs paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357 (26): 2666–76.11.von Minckwitz G, Untch M, Blohmer J.U et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30 (15): 1796–804.12.Pivot X.B, Li R.K, Thomas E.S et al. Activity of ixabepilone in oestrogen receptor - negative and oestrogen receptor - progesterone receptor - human epidermal growth factor receptor 2-negative metastatic breast cancer. Eur J Cancer 2009; 45 (17): 2940–6.13.Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med 2012; 12 (1): 96–110.14.Robert N.J, Diéras V, Glaspy J et al. RIBBON-1: randomized, double - blind, placebo - controlled, phase III trial of chemotherapy with or without bevacizumab for first - line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29 (10): 1252–60. http://doi:10.1200/ JCO.2010.28.098215.Miles D.W, Diéras V, Cortés J et al. First - line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013.16.Brufsky A.M, Hurvitz S, Perez et al. RIBBON-2: a randomized, double - blind, placebo - controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second - line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011; 29 (32): 4286–93.